Scarica l'app Stockscreener
36.10
0.33%
-0.12
Pre-mercato:
36.11
0.010
+0.03%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Precedente Chiudi:
$36.22
Aprire:
$36.55
Volume 24 ore:
266.08K
Relative Volume:
0.76
Capitalizzazione di mercato:
$1.99B
Reddito:
$651.97M
Utile/perdita netta:
$59.71M
Rapporto P/E:
49.45
EPS:
0.73
Flusso di cassa netto:
$172.03M
1 W Prestazione:
+2.41%
1M Prestazione:
+6.40%
6M Prestazione:
+31.23%
1 anno Prestazione:
+29.72%
Intervallo 1D:
$36.10
$37.21
Intervallo di 1 settimana:
$34.88
$37.21
Portata 52W:
$25.53
$39.37
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
Supernus Pharmaceuticals Inc
Settore
Telefono
301-838-2500
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Confronta SUPN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
36.10 | 1.99B | 651.97M | 59.71M | 172.03M | 0.73 |
|
ZTS
Zoetis Inc
|
178.71 | 80.63B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.58 | 43.32B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.49 | 42.77B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.69 | 18.91B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.36 | 16.08B | 15.05B | -883.30M | 1.89B | 1.53 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Ripresa | Jefferies | Buy |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-04-13 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Ripresa | Jefferies | Hold |
| 2019-11-08 | Downgrade | Berenberg | Buy → Hold |
| 2019-11-07 | Downgrade | Stifel | Buy → Hold |
| 2019-11-06 | Downgrade | Jefferies | Buy → Hold |
| 2018-11-12 | Reiterato | B. Riley FBR | Buy |
| 2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-08 | Aggiornamento | Stifel | Hold → Buy |
| 2017-10-19 | Iniziato | FBR & Co. | Buy |
| 2017-09-19 | Downgrade | Stifel | Buy → Hold |
| 2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Iniziato | Janney | Neutral |
| 2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2015-11-05 | Reiterato | Northland Capital | Outperform |
| 2015-10-28 | Iniziato | Northland Capital | Outperform |
Mostra tutto
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Segall Bryant & Hamill LLC Invests $791,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
SUPN (Supernus Pharmaceuticals) Operating Margin % : 22.67% (As of Sep. 2024) - GuruFocus.com
Connor Clark & Lunn Investment Management Ltd. Has $6.70 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Pacer Advisors Inc. Buys 403,028 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals (LTS:0LB2) EBITDA per Share : $2.79 (TTM As of Sep. 2024) - GuruFocus.com
Supernus Pharmaceuticals (FRA:S49) Degree of Operating Leve - GuruFocus.com
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2024 Earnings Call Transcript - MSN
Mutual of America Capital Management LLC Sells 75,782 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
56,885 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by State of New Jersey Common Pension Fund D - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Purchased by Principal Financial Group Inc. - MarketBeat
Los Angeles Capital Management LLC Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
(SUPN) Technical Data - Stock Traders Daily
ARMISTICE CAPITAL, LLC Adjusts Stake in Supernus Pharmaceuticals Inc - GuruFocus.com
SUPNSupernus Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Supernus Pharmaceuticals Inc (SUPN) Shares Gap Down to $36.57 on Nov 14 - GuruFocus.com
Have Supernus Pharmaceuticals Insiders Been Selling Stock? - Simply Wall St
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference - The Manila Times
Supernus Pharmaceuticals CEO to Present at Jefferies London Healthcare Conference | SUPN Stock News - StockTitan
GSA Capital Partners LLP Acquires 43,086 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth (NASDAQ:SUPN) - Seeking Alpha
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Georges Gemayel Sells 14,213 Shares - MarketBeat
Insider Selling: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) SVP Sells 15,000 Shares of Stock - MarketBeat
Insider Selling: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Sells 125,000 Shares of Stock - MarketBeat
Supernus Pharmaceuticals director sells shares worth $520,480 - Investing.com
Supernus Pharmaceuticals SVP Frank Mottola sells $554,700 in stock - Investing.com
Supernus Pharmaceuticals SVP Frank Mottola sells $554,700 in stock By Investing.com - Investing.com UK
Supernus: Q3 Earnings Snapshot - AOL
Supernus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings call: Supernus Pharmaceuticals reported a significant increase in total revenue - Investing.com Nigeria
Supernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 1-Year High After Strong Earnings - MarketBeat
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highli - GuruFocus.com
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates - MSN
Supernus Pharmaceuticals Reports Strong Q3 2024 Results - TipRanks
Supernus Pharmaceuticals Q3 2024 Earnings: EPS of $0.69 Beats Es - GuruFocus.com
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Supernus Announces Third Quarter 2024 Financial Results - GlobeNewswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Posts Quarterly Earnings Results, Beats Estimates By $0.25 EPS - MarketBeat
Supernus Pharmaceuticals (FRA:S49) PE Ratio : 387.50 (As of Nov. 04, 2024) - GuruFocus.com
Q3 2024 Supernus Pharmaceuticals Inc Earnings Call Transcript - GuruFocus.com
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Supernus Pharmaceuticals, Inc. Increases Earnings Guidance for the Year 2024 - Marketscreener.com
(SUPN) On The My Stocks Page - Stock Traders Daily
Macquarie Group Ltd Adjusts Stake in Supernus Pharmaceuticals Inc - GuruFocus.com
Stephens Investment Management Group LLC Buys 33,710 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Dimensional Fund Advisors LP Expands Stake in Supernus Pharmaceu - GuruFocus.com
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 - The Manila Times
Supernus Presents Promising Data from Open-Label Phase 2a - GlobeNewswire
Supernus Pharmaceuticals reports rapid depression treatment response By Investing.com - Investing.com Australia
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):